Joon Young Kim1, Hala Tfayli2, Sara F Michaliszyn3, SoJung Lee1, Alexis Nasr1, Silva Arslanian4. 1. Division of Weight Management and Wellness, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 2. Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon. 3. Human Performance and Exercise Science, Youngstown State University, Youngstown, Ohio. 4. Division of Weight Management and Wellness, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Division of Pediatric Endocrinology, Metabolism and Diabetes Mellitus, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: Silva.arslanian@chp.edu.
Abstract
PURPOSE: Anti-Müllerian hormone (AMH) is proposed as a biomarker of polycystic ovary syndrome (PCOS). This study investigated: (1) AMH concentrations in obese adolescents with PCOS versus without PCOS; (2) the relationship of AMH to sex steroid hormones, adiposity, and insulin resistance; and (3) the optimal AMH value and the multivariable prediction model to determine PCOS in obese adolescents. METHODS: AMH levels were measured in 46 obese PCOS girls and 43 obese non-PCOS girls. Sex steroid hormones, clamp-measured insulin sensitivity and secretion, body composition, and abdominal adiposity were evaluated. Logistic regression and receiver-operating characteristic curve analyses were used, and multivariate prediction models were developed to test the utility of AMH for the diagnosis of PCOS. RESULTS: AMH levels were higher in obese PCOS versus non-PCOS girls (8.3 ± .6 vs. 4.3 ± .4 ng/mL, p < .0001), of comparable age and puberty. AMH concentrations correlated positively with age in both groups, total and free testosterone in PCOS girls only, abdominal adipose tissue in non-PCOS girls, with no correlation to in vivo insulin sensitivity and secretion in either groups. A multivariate model including AMH (cutoff 6.26 ng/mL, area under the curve .788) together with sex hormone-binding globulin and total testosterone exhibited 93.4% predictive power for diagnosing PCOS. CONCLUSIONS: AMH may be a useful biomarker for the diagnosis of PCOS in obese adolescent girls.
PURPOSE: Anti-Müllerian hormone (AMH) is proposed as a biomarker of polycystic ovary syndrome (PCOS). This study investigated: (1) AMH concentrations in obese adolescents with PCOS versus without PCOS; (2) the relationship of AMH to sex steroid hormones, adiposity, and insulin resistance; and (3) the optimal AMH value and the multivariable prediction model to determine PCOS in obese adolescents. METHODS:AMH levels were measured in 46 obese PCOS girls and 43 obese non-PCOSgirls. Sex steroid hormones, clamp-measured insulin sensitivity and secretion, body composition, and abdominal adiposity were evaluated. Logistic regression and receiver-operating characteristic curve analyses were used, and multivariate prediction models were developed to test the utility of AMH for the diagnosis of PCOS. RESULTS:AMH levels were higher in obese PCOS versus non-PCOS girls (8.3 ± .6 vs. 4.3 ± .4 ng/mL, p < .0001), of comparable age and puberty. AMH concentrations correlated positively with age in both groups, total and free testosterone in PCOSgirls only, abdominal adipose tissue in non-PCOSgirls, with no correlation to in vivo insulin sensitivity and secretion in either groups. A multivariate model including AMH (cutoff 6.26 ng/mL, area under the curve .788) together with sex hormone-binding globulin and total testosterone exhibited 93.4% predictive power for diagnosing PCOS. CONCLUSIONS:AMH may be a useful biomarker for the diagnosis of PCOS in obese adolescent girls.
Authors: Christopher R McCartney; Susan K Blank; Kathleen A Prendergast; Sandhya Chhabra; Christine A Eagleson; Kristin D Helm; Richard Yoo; R Jeffrey Chang; Carol M Foster; Sonia Caprio; John C Marshall Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: Wouter J K Hehenkamp; Caspar W N Looman; Axel P N Themmen; Frank H de Jong; E R Te Velde; Frank J M Broekmans Journal: J Clin Endocrinol Metab Date: 2006-06-27 Impact factor: 5.958
Authors: Alexandra L L Durlinger; Maria J G Gruijters; Piet Kramer; Bas Karels; Holly A Ingraham; Mark W Nachtigal; Jan Th J Uilenbroek; J Anton Grootegoed; Axel P N Themmen Journal: Endocrinology Date: 2002-03 Impact factor: 4.736
Authors: Joop S E Laven; Annemarie G M G J Mulders; Jenny A Visser; Axel P Themmen; Frank H De Jong; Bart C J M Fauser Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: Madison T Ortega; Lauren Carlson; John A McGrath; Tairmae Kangarloo; Judith Mary Adams; Patrick M Sluss; Geralyn Lambert-Messerlian; Natalie D Shaw Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958